CAR-T Cells in the Treatment of Malignant Hematological Tumors
NCT05619861 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2022-11-17
Summary
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
Conditions
- Lymphoma, B-Cell
- Leukemia, B-cell
- Leukemia, T-Cell
- Multiple Myeloma
Interventions
- BIOLOGICAL
-
CAR-T
Patients will receive CAR-T treatment
Sponsors & Collaborators
-
Cangzhou People's Hospital
collaborator OTHER -
Hebei Senlang Biotechnology Inc., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 14 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-04-27
- Primary Completion
- 2023-01-26
- Completion
- 2023-12-26
Countries
- China
Study Locations
More Related Trials
-
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
NCT06647329 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies
NCT04008394 ·Status: UNKNOWN ·Phase: PHASE1
-
Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NCT05488132 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
NCT05909527 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
CAR T Cells for Refractory B Cell Malignancy
NCT02963038 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
NCT04916860 ·Status: UNKNOWN ·Phase: NA
-
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
NCT06730256 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NCT06783816 ·Status: RECRUITING ·Phase: NA
-
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
NCT04008524 ·Status: AVAILABLE
-
CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
NCT03312205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies
NCT04007978 ·Status: UNKNOWN ·Phase: PHASE1
-
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05309213 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
NCT04610125 ·Status: UNKNOWN ·Phase: NA
-
Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma
NCT05745181 ·Status: RECRUITING ·Phase: PHASE2
-
Universal CAR-γδT Cell Injection in the AML Patients
NCT05388305 ·Status: UNKNOWN ·Phase: NA
-
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
NCT05105867 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
NCT06756321 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors
NCT04665076 ·Status: UNKNOWN ·Phase: NA
-
CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
NCT06365671 ·Status: RECRUITING ·Phase: PHASE2
-
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
NCT03638206 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04546906 ·Status: UNKNOWN ·Phase: NA
-
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
NCT04008251 ·Status: UNKNOWN ·Phase: PHASE1
-
Donor-derived CAR-T Cells in the Treatment of AML Patients
NCT04766840 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
NCT03960060 ·Status: TERMINATED ·Phase: PHASE1
-
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
NCT05480501 ·Status: UNKNOWN ·Phase: EARLY_PHASE1